Review papers with raw data transparency

Concise verdict

URCAS is a modular, protease‑driven genetic platform that couples programmable protease circuits to an aquaporin MRI reporter (hAqp1) to generate large, target‑specific diffusion MRI signals across multiple mammalian cell types, enabling sensors for proteases, small molecules, protein interactions, logic gates, and calcium without target‑specific protein engineering URCAS platform summary

A rigorous review of A programmable genetic platform for engineering noninvasive biosensors

High‑level summary

This manuscript introduces URCAS (universal reporter circuit‑based activatable sensors), a programmable framework that uses protease‑regulated engineering of human aquaporin‑1 (hAqp1) reporters to produce large, switchable diffusion MRI readouts. The authors implement two mechanistic families: DD‑URCAS (protease excises a destabilizing domain leading to protein stabilization and membrane localization) and ER‑URCAS (protease removes an ER retention tag to traffic preformed hAqp1 to the membrane). They demonstrate modularity by substituting protease cleavage sites, using split proteases, building AND logic, sensing small molecules and calcium, and validating across multiple cell types (CHO, PC12, Jurkat, MDA‑MB‑231, U87) with quantitative diffusion MRI and orthogonal biochemical assays Abstract summary of URCAS

Key experimental results (data‑driven)

• DD‑URCAS with hAqp1 fused to FKBP12‑DD produced a 92 ± 4% increase in diffusivity upon TEVP expression (CHO cells) and improved to 124 ± 3% when three cleavage sites were used, indicating multivalency improves activation (akin to avidity) DD‑URCAS cleavage site effect
• Orthogonal proteases TVMVP and HCVP produced 75 ± 3% and 67 ± 4% diffusivity increases respectively, supporting straightforward transfer of the architecture to other proteases Orthogonal protease activation
• Split TEVP sensors allowed sensing of protein interactions and calcium: p3/p4 heterodimerizer split TEVP produced ~165 ± 7% change; calmodulin/RS20 split TEVP produced ~157 ± 7% response upon ionomycin; FKBP/Frb rapamycin system reaches ~136% with roughly half‑max in ~2 hours, showing dynamic responsiveness Split TEVP dynamics and calciumsensing
• ER‑URCAS via KKYL retention tags produced robust diffusivity increases across cell types (range reported 98–195%), showing trafficking based approach yields large signals and is less dependent on degradation pathways ER‑URCAS across cell types

Mechanistic validation and controls

The authors corroborated MRI diffusion changes with Western blots and confocal imaging showing membrane localization after proteolytic activation, and used lysosomal and proteasomal inhibitors (chloroquine and MG132) to probe degradation pathways for DD‑URCAS (chloroquine stabilized fusion protein in vesicles but did not produce membrane diffusivity, indicating trafficking vs degradation distinction) Degradation and trafficking controls

Strengths

• Modularity and generality: same reporter core repurposed for many inputs by swapping protease circuits and using split / degron / trafficking modules, reducing need for de novo protein engineering Modularity claim
• Quantitative, multi‑modal validation: diffusion MRI, RT‑qPCR, Westerns, confocal microscopy and small molecule perturbations align and support the mechanistic story Multimodal validation
• Robust signal sizes: many sensor implementations produce >90% diffusivity increases, often >150%, which is large relative to typical MRI reporter changes and thus promising for in vivo translation potential pending delivery and immunogenicity testing Reported signal magnitudes

Limitations, blindspots, and critical caveats

1. In vitro only: all experiments were performed in cultured cell pellets; the paper lacks in vivo data demonstrating sensor activation in tissues where diffusion MRI is confounded by extracellular matrix, perfusion, edema, inflammation, or cell death—factors that can change water diffusion independent of reporter activation. The authors acknowledge the need for in vivo work Need for in vivo validation
2. Potential confounders for diffusion MRI signals: cell membrane permeability, cell death, necrosis, swelling, or changes in extracellular fraction can alter diffusivity measurements. Although the authors use biochemical controls, translation into tissues will demand stringent orthogonal readouts (histology, co-registered functional imaging, cell viability assays) to exclude nonspecific effects Authors acknowledge diffusion MRI confounders
3. Immunogenicity and safety: the platform relies on viral proteases (and engineered TEVP variants). In vivo use will require evaluation of immune responses to nonhuman proteases, off‑target cleavage, and safety of long‑term expression; the paper notes these as outstanding questions but does not present data Immunogenicity concern note
4. Quantitative dynamic range and kinetics: some constructs show background activation (truncated split TEVP had background activity), and kinetics vary (ER‑URCAS half‑max ~2 h for rapamycin). For biological events that are rapid or transient, additional engineering to tune on/off kinetics and reversibility will be necessary Kinetics and background activation
5. Data and materials availability constraints: authors say data are available on request and plasmids via MTA; for reproducibility and rapid community adoption, public deposition of sequences, plasmids, and imaging protocols would accelerate validation and reduce invisible friction from MTAs Data availability statement

Reproducibility and methodological clarity

Methods are described in detail for cell constructs, protease variants, MRI acquisition on cell pellets, and biochemical characterizations. Reported n>=3 measurements, quantitative RT‑qPCR, and multiple orthogonal validations increase confidence. However, the absence of public plasmid sequences, raw diffusion maps, and full MRI acquisition parameters in a public repository limits immediate, independent reproduction; authors offer materials on request Methods summary

Where the platform could go next (recommendations)

1. In vivo proof of concept: small animal (rodent) xenograft or localized cell delivery with co-registered diffusion MRI, histology, and immunogenicity assays to test signal specificity and dynamics in tissue contexts.
2. Public release of plasmid sequences, constructs, and raw imaging datasets in accessible repositories (Addgene, GenBank, Dryad / OpenNeuro) to maximize reproducibility and community building.
3. Engineering for reversibility and tunable kinetics: add degron systems that can be re‑applied, or use orthogonal small‑molecule actuators to tune on/off speed for transient biological signals.
4. Evaluate alternative MRI reporters and modalities: combining URCAS with reporters that affect T1/T2 contrast or CEST could broaden the toolkit for contexts where diffusion MRI is noisy.

Data visualization: reproduced core quantitative panel

Overall evaluation

The paper presents a carefully executed, compelling, and modular platform that materially advances the toolbox for genetically encoded, noninvasive biosensing for deep tissues. It convincingly demonstrates that protease‑based circuit modules can convert diverse molecular inputs into large, quantifiable diffusion MRI outputs using a common hAqp1 reporter core. The most important next step is rigorous in vivo demonstration and open sharing of constructs and raw imaging data to test robustness in tissue environments and accelerate adoption Conclusions summary

Author reviews